Humacyte’s (HUMA) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Humacyte (NASDAQ:HUMA) in a research note published on Thursday,Benzinga reports. The firm currently has a $25.00 price target on the stock.

Other research analysts have also recently issued research reports about the stock. Piper Sandler set a $6.00 target price on shares of Humacyte and gave the company a “neutral” rating in a research report on Friday, October 18th. Benchmark restated a “buy” rating and issued a $15.00 price objective on shares of Humacyte in a report on Thursday, October 10th. BTIG Research reiterated a “buy” rating and issued a $10.00 target price on shares of Humacyte in a report on Friday, October 18th. Cantor Fitzgerald reissued an “overweight” rating and issued a $13.00 target price on shares of Humacyte in a research report on Friday, September 20th. Finally, TD Cowen restated a “buy” rating and set a $10.00 price target on shares of Humacyte in a research report on Friday, October 18th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Humacyte currently has a consensus rating of “Buy” and a consensus target price of $13.00.

Humacyte Stock Performance

Shares of Humacyte stock opened at $4.52 on Thursday. The firm has a market cap of $568.89 million, a PE ratio of -3.35 and a beta of 1.47. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.61. Humacyte has a 52 week low of $2.43 and a 52 week high of $9.97. The business’s fifty day simple moving average is $5.31 and its 200-day simple moving average is $6.19.

Insider Activity at Humacyte

In other news, Director Brady W. Dougan sold 352,112 shares of the business’s stock in a transaction dated Thursday, August 29th. The stock was sold at an average price of $6.35, for a total value of $2,235,911.20. Following the completion of the sale, the director now directly owns 3,677,262 shares of the company’s stock, valued at approximately $23,350,613.70. The trade was a 8.74 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Kathleen Sebelius sold 5,182 shares of the company’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $5.40, for a total value of $27,982.80. Following the completion of the sale, the director now directly owns 40,276 shares of the company’s stock, valued at approximately $217,490.40. This trade represents a 11.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 2,584,153 shares of company stock valued at $13,476,796 over the last ninety days. Insiders own 11.20% of the company’s stock.

Hedge Funds Weigh In On Humacyte

Institutional investors have recently modified their holdings of the business. Vanguard Group Inc. grew its position in Humacyte by 28.7% during the 1st quarter. Vanguard Group Inc. now owns 4,019,681 shares of the company’s stock worth $12,501,000 after purchasing an additional 896,415 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Humacyte during the first quarter worth about $197,000. ARS Investment Partners LLC acquired a new position in Humacyte in the 2nd quarter valued at about $559,000. Bank of New York Mellon Corp lifted its position in Humacyte by 62.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 254,013 shares of the company’s stock worth $1,219,000 after acquiring an additional 97,931 shares during the period. Finally, Principal Financial Group Inc. purchased a new stake in shares of Humacyte in the second quarter valued at about $83,000. 44.71% of the stock is owned by institutional investors and hedge funds.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.